Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-05-31
2011-05-31
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S178100, C530S391700
Reexamination Certificate
active
07951920
ABSTRACT:
The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.
REFERENCES:
patent: 5202238 (1993-04-01), Fell et al.
patent: 5204244 (1993-04-01), Fell et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 5871732 (1999-02-01), Burkly et al.
patent: 5876969 (1999-03-01), Fleer et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6060065 (2000-05-01), Barney et al.
patent: 6093794 (2000-07-01), Barney et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6258782 (2001-07-01), Barney et al.
patent: 6348568 (2002-02-01), Barney et al.
patent: 6479055 (2002-11-01), Bolognesi et al.
patent: 6528625 (2003-03-01), Wu et al.
patent: 6610834 (2003-08-01), Lobo
patent: 6656906 (2003-12-01), Barney et al.
patent: 7138496 (2006-11-01), Hua et al.
patent: 2001/0000241 (2001-04-01), Li et al.
patent: 2002/0048786 (2002-04-01), Rosen et al.
patent: 2002/0061834 (2002-05-01), Rosen et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2002/0146415 (2002-10-01), Olson et al.
patent: 2002/0147147 (2002-10-01), Molling et al.
patent: 2002/0147311 (2002-10-01), Gillies et al.
patent: 2003/0003440 (2003-01-01), Lopalco
patent: 2003/0044411 (2003-03-01), Olson et al.
patent: 2003/0049227 (2003-03-01), Gillies et al.
patent: 2003/0049251 (2003-03-01), Barbas et al.
patent: 2003/0099645 (2003-05-01), Lobo
patent: 2003/0100058 (2003-05-01), Roschke et al.
patent: 2003/0103984 (2003-06-01), Kohler
patent: 2003/0104581 (2003-06-01), Hoess et al.
patent: 2003/0152913 (2003-08-01), Hua et al.
patent: 2003/0165988 (2003-09-01), Hua et al.
patent: 2003/0166024 (2003-09-01), Rosen et al.
patent: 2003/0166870 (2003-09-01), Wu et al.
patent: 2003/0195348 (2003-10-01), Combadiere et al.
patent: 2003/0215421 (2003-11-01), McDonald et al.
patent: 2003/0226155 (2003-12-01), Sadeghi et al.
patent: 2003/0228306 (2003-12-01), Olson et al.
patent: 2004/0043033 (2004-03-01), Green
patent: 2005/0008649 (2005-01-01), Shin et al.
patent: 2005/0100991 (2005-05-01), Rosen et al.
patent: 2005/0114037 (2005-05-01), Desjarlais et al.
patent: 2006/0051346 (2006-03-01), Wijdenes
patent: 2006/0121480 (2006-06-01), Fung
patent: 2007/0036796 (2007-02-01), Brandt et al.
patent: 0 512 112 (1991-11-01), None
patent: 0 307 434 (1993-09-01), None
patent: 0 512 112 (1997-05-01), None
patent: 0 442 724 (1999-10-01), None
patent: 1 207 202 (2002-05-01), None
patent: 0 840 618 (2003-04-01), None
patent: 1 161 456 (2004-12-01), None
patent: 1 266 965 (2006-05-01), None
patent: 0 854 885 (2006-12-01), None
patent: 1 346 731 (2006-12-01), None
patent: 1 144 006 (2007-10-01), None
patent: WO 91/09966 (1991-07-01), None
patent: WO 92/09305 (1992-06-01), None
patent: WO 94/26910 (1994-11-01), None
patent: WO 96/40191 (1996-12-01), None
patent: WO 97/46697 (1997-12-01), None
patent: WO 98/33523 (1998-08-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/59615 (1999-11-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/69902 (2000-11-01), None
patent: WO 01/42308 (2001-06-01), None
patent: WO 01/43779 (2001-06-01), None
patent: WO 01/58915 (2001-08-01), None
patent: WO 01/58916 (2001-08-01), None
patent: WO 02/22077 (2002-03-01), None
patent: WO 02/083172 (2002-10-01), None
patent: WO 03/033666 (2003-04-01), None
patent: WO 03/066830 (2003-08-01), None
patent: WO 03/072766 (2003-09-01), None
patent: WO 2004/029074 (2004-04-01), None
patent: WO 2004/085505 (2004-10-01), None
patent: WO 2004/101739 (2004-11-01), None
patent: WO 2004/103312 (2004-12-01), None
patent: WO 2004/108885 (2004-12-01), None
patent: WO 2005/067960 (2005-07-01), None
patent: WO 2006/103100 (2006-10-01), None
patent: WO 2007/045463 (2007-04-01), None
patent: WO 2007/045465 (2007-04-01), None
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1893.
Mac Callum, Martin, and Thronton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemcial and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, McKay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Wang, L.X. et. al., “Carbohydrate-Centered Maleimide Cluster as a New Type of Templates for Multivalent Peptide Assembling: Synthesis of Multivalent HIV-1 gp41 Peptides,”Bioorganic&Medicinal Chem. (2003) vol. 11, Issue 1, pp. 159-166.
Wild, C. et al., “Propensity for a Leucine Zipper-like Domain of Human Immunodeficiency Virus Type 1 gp41 to Form Oligomers Correlates with a Role in Virus-induced fusion rather than assembly of the Glycoprotein Complex,”Proc. Natl. Acad. Sci. (1994) vol. 91, pp. 12676-12680.
Bar, S. et. al. “Role of the Ectodomain of the gp41 Transmembrane Envelope Protein of Human Immunodeficiency Virus type 1 in late Steps of the Membrane Fusion Process,”J. Virology, 2004, vol. 78 (2), pp. 811-820.
Brady, et. al. “The Structure of CD4,”Curr. Topic Microbiol. Immunol. 1996, vol. 205, pp. 1-17.
Brenneman, et. al. “Acquired Immune Deficiency Syndrome and the Developing Nervous System,”International Rev. Neurobiology, 1990, vol. 32, pp. 305-353.
Brunhouse, R., et al.,“Isotypes of IgG: Comparison of the Primary Stuctures of Three Pairs of Isotypes which Differ in their Ability to Activate complement,”Molecular Immunology. 16 (1979) 907-917.
Burnette, “Western Blotting: Electrophoretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A,”Analytical Biochem. 1981, vol. 112, pp. 195-203.
Burton, D.R. et. al., “The C1q Receptor Site on Immunoglobulin G,”Nature(1980) vol. 288, pp. 338-344.
Cohen, J. “Likely HIV Cofactor Found,”Science1996, vol. 272, pp. 809-810.
Cocchi, F. et. al., “Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells,” Science (1995) vol. 270 pp. 1811-1815.
Dean, M., et al., “Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene,”Science273 (1996) 1856-1862.
Edelman, G.M., et al., “The Covalent Structure of an Entire—G Immunoglobin Molecule,”Natl. Acad. Sci. USA63 (1969
Brandt Michael
Fischer Stephan
Kopetzki Erhard
Sankuratri Suryanarayana
Schumacher Ralf
Gussow Anne M.
Hall Robert C.
Roche Palo Alto LLC
LandOfFree
Conjugate of an antibody against CCR5 and an antifusogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugate of an antibody against CCR5 and an antifusogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugate of an antibody against CCR5 and an antifusogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2671295